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Abstract
Background: To ensure patients continue to get early access to antibiotics at admission, while also safely reducing
antibiotic use in hospitals, one needs to target the continued need for antibiotics as more diagnostic information
becomes available. UK Department of Health guidance promotes an initiative called ‘Start Smart then Focus’: early
effective antibiotics followed by active ‘review and revision’ 24–72 h later. However in 2017, < 10% of antibiotic
prescriptions were discontinued at review, despite studies suggesting that 20–30% of prescriptions could be stopped
safely.
Methods/design: Antibiotic Review Kit for Hospitals (ARK-Hospital) is a complex ‘review and revise’ behavioural
intervention targeting healthcare professionals involved in antibiotic prescribing or administration in inpatients
admitted to acute/general medicine (the largest consumers of non-prophylactic antibiotics in hospitals). The primary
study objective is to evaluate whether ARK-Hospital can safely reduce the total antibiotic burden in acute/general
medical inpatients by at least 15%. The primary hypotheses are therefore that the introduction of the behavioural
intervention will be non-inferior in terms of 30-day mortality post-admission (relative margin 5%) for an acute/general
medical inpatient, and superior in terms of defined daily doses of antibiotics per acute/general medical admission (co-
primary outcomes). The unit of observation is a hospital organisation, a single hospital or group of hospitals organised
with one executive board and governance framework (National Health Service trusts in England; health boards in
Northern Ireland, Wales and Scotland). The study comprises a feasibility study in one organisation (phase I), an internal
pilot trial in three organisations (phase II) and a cluster (organisation)-randomised stepped-wedge trial (phase III)
targeting a minimum of 36 organisations in total. Randomisation will occur over 18months from November 2017 with
a further 12 months follow-up to assess sustainability. The behavioural intervention will be delivered to
healthcare professionals involved in antibiotic prescribing or administration in adult inpatients admitted to
acute/general medicine. Outcomes will be assessed in adult inpatients admitted to acute/general medicine,
collected through routine electronic health records in all patients.
Discussion: ARK-Hospital aims to provide a feasible, sustainable and generalisable mechanism for increasing
antibiotic stopping in patients who no longer need to receive them at ‘review and revise’.
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Background
Antimicrobial resistance is one of the most important
global public health risks recognised by the UK govern-
ment [1] and the World Health Organization (WHO)
[2], with increasing impacts on health [3]. It is increasing
year-on-year, particularly in common Gram-negative
bacteria [4, 5]; for example, the incidence of Escherichia
coli bloodstream infections resistant to the most com-
monly used antibiotics has quadrupled over the last dec-
ade in Oxfordshire [6].
The only way to reduce the selective pressure on bac-
teria to develop resistance is to reduce antibiotic use [7,
8]. Resistant strains emerge rapidly in faecal [9] and
nasal flora [10–12] during antibiotic treatment. Detect-
able resistance in these carried organisms wanes over
time, but it can persist [13] and is still associated with
developing antibiotic-resistant infections [14, 15], as is
prior antibiotic use [15, 16]. Reducing population-level
antibiotic consumption can significantly reduce drug re-
sistance [17], although this is not a simple cause-effect
relationship. Most bacterial resistance is due to genes car-
ried on mobile genetic elements which move within and
between bacterial species. Thus, removing selection pres-
sure from one antibiotic will not always lead to loss of re-
sistance, e.g. if other beneficial genes (or genes conferring
resistance to other antibiotics still in use) are co-carried
on the same mobile element [18–20]. Nevertheless, coun-
tries with higher antibiotic consumption generally have
higher rates of antibiotic-resistant infections [21].
Whilst hospital prescribing accounts for < 20% of the
antibiotics consumed in England, around two-thirds of
prescriptions for ‘broad-spectrum’ agents (active against
a wide variety of bacteria, including some antibiotic-
resistant strains) are made in hospitals [5]. These broad-
spectrum antibiotics have the greatest potential to drive
future resistance, and, in contrast to primary care, hos-
pital prescribing continues to increase (by 7% over
2013–2018 [5]). Aside from resistance, antibiotics are
also associated with non-trivial rates (~ 20%) of adverse
drug reactions [22].
Avoiding or delaying prescription are two strategies
that successfully lower antibiotic consumption in pri-
mary care [23, 24]. However, in contrast to primary care
patients, a considerable proportion of those presenting
to hospital will genuinely have bacterial infections and
need antibiotics. If a patient has a life-threatening bac-
terial infection, delays in administering effective antibi-
otics of even one hour increase mortality risk [25]. The
challenge is accurately identifying these patients and
their infecting microorganisms, which is difficult and
takes time. This provides the rationale for prescribing
broad-spectrum antibiotics whenever infection is sus-
pected at admission (see e.g. ‘Surviving Sepsis’ [26]),
since these should kill any infecting bacteria whilst
(in theory) not harming patients without bacterial
infections.
To ensure patients continue to get early access to anti-
biotics at admission, the safe reduction of antibiotic use
in hospitals therefore needs to target the continued need
for, and choice of, antibiotics as more diagnostic infor-
mation becomes available. 2011 Department of Health
(DH) guidance promotes an initiative called ‘Start Smart
then Focus’ [27, 28]: early effective antibiotics followed
by active ‘review and revision’ 24–72 h later. Five op-
tions are recommended: stop; switch from intravenous
to oral administration; continue and review again;
change (if possible to antibiotics with narrower
spectrum of activity); or move to outpatient intraven-
ous antibiotic therapy.
However, a 2013 survey of National Health Service
(NHS) antibiotic pharmacists found that although 95%
of 105 responding English trusts included early anti-
biotic review in their policies/guidelines, only 48% con-
ducted any compliance monitoring [29]. Where
compliance was monitored, relatively few (< 20%) pre-
scription changes of any kind were made. This agrees
with studies reporting clinicians’ reluctance to modify
antibiotic prescribing decisions made by others, even
when a patient’s clinical status has evolved [30] and re-
flects the complexity of decision making on antibiotic
prescribing [31]. Trust policies frequently recommended
antibiotic durations of ≥ 7 days [29], suggesting lack of
review could lead to substantial overuse. Even by 2017,
< 10% of antibiotic prescriptions were discontinued at
review [32], despite studies suggesting that 20–30% of
prescriptions could be stopped safely [33]. Despite con-
siderable variation in local guideline-recommended anti-
biotic duration and practice [29], there are no data
showing whether or not trusts which routinely use fewer
antibiotics have higher rates of adverse outcomes.
This failure of prescribers to change or stop antibiotics
is perhaps unsurprising given the lack of evidence to in-
form how ‘review and revise’ should be implemented. Of
221 hospital antimicrobial stewardship interventions in-
cluded in a Cochrane review [34], only 14 even collected
duration of antibiotic therapy as an analysable outcome,
Walker et al. Trials          (2019) 20:421 Page 2 of 16
let alone directly targeted it; many of these studies
evaluated the introduction of procalcitonin testing as a
mechanism to reduce antibiotic durations. Other inter-
ventions included introducing guidelines/policies and
education/feedback. Interventions specifically designed
to reduce antibiotic duration were not evaluated as a
category, but overall duration of antibiotic treatment de-
creased by 1.95 days with stewardship interventions.
One large study (n = 462) [35] found an intervention in-
corporating face-to-face pharmacist feedback signifi-
cantly reduced antibiotic durations for lower respiratory
tract infections in intensive care. However, another study
found no impact of prescription review by telephone
[36], illustrating the importance of specific intervention
components.
The challenge is developing feasible, sustainable and
generalisable ‘review and revise’ interventions given the
complexity of hospital antibiotic prescribing. Doctors
need to balance the risks of under-treating infection in
patients against risks of antibiotic-resistant infections in
the future, making practical choices about specific drug,
dose and duration given clinical indication, within the
cultural context of multidisciplinary secondary care [31].
In the near future, faster and more accurate diagnostic
tests for infection will likely become available, reducing
the time to identify an infecting organism and its anti-
biotic susceptibilities. It is highly unlikely that these tests
will remove the need to prescribe broad-spectrum anti-
biotics for severely ill patients at admission, but they will
bring the time frame for ‘review and revise’ decisions
forwards and increase potential gains from optimally
implementing this ‘review and revise’ approach.
Methods
Objective
The primary objective of ARK-Hospital is to evaluate
whether a multifaceted ‘review and revise’ behavioural
intervention targeting healthcare professionals involved in
antibiotic prescribing or administration in inpatients ad-
mitted to acute/general medicine (the largest consumers
of non-prophylactic antibiotics in hospitals [37]) can safely
reduce total antibiotic burden in acute/general medical in-
patients by at least 15%. The primary hypotheses are
therefore that the introduction of the behavioural inter-
vention will be non-inferior in terms of 30-day mortality
post-admission for an acute/general medical inpatient and
superior in terms of defined daily doses (DDDs) of antibi-
otics per acute/general medical admission.
Design
The study comprises three phases: a feasibility study
(phase I), an internal pilot trial (phase II) and a cluster
(organisation)-randomised stepped-wedge trial (phase
III) in which each organisation acts as its own control.
In the phase I feasibility study, the intervention was
implemented in one organisation on 18 April 2017 to
test the feasibility and acceptability of trial procedures
(e.g. clinical research governance, trial documents), the
trial intervention (e.g. usage, engagement, adherence,
completion, fidelity) and data collection procedures (e.g.
audit results, questionnaires, electronic health record
data). (Cross ELA, et al.: Adaptation and Implementa-
tion of the ARK (Antibiotic Review Kit) Intervention to
Safely and Substantially Reduce Antibiotic Use in Hospi-
tals: a Feasibility Study, submitted. [38])
The phase II internal pilot formed the first phase of the
substantive trial evaluating the impact of the intervention
package on healthcare professionals and inpatients/carers.
The intervention was iteratively implemented in three or-
ganisations between 25 September 2017 and 20 November
2017, using the ACCEPT approach [39] to identify neces-
sary refinements and as the basis for the decision to in-
clude long-term follow-up from these phase II pilot sites
within the main trial evaluation (phase III).
In the phase III main trial, the intervention is being
implemented in two to four organisations per month
over 18 months from 12 February 2018 to 24 June 2019,
to reach the total sample size of a minimum of 36 orga-
nisations for evaluation (including phase II internal pilot
sites). A further 12 months’ follow-up in all organisations
will assess the sustainability of any intervention effect.
The unit of randomisation is the organisation, a single
or group of hospital(s) organised with one executive
board and governance framework. In England these are
called trusts; in Northern Ireland, Scotland and Wales
they are called health boards. Organisation is the unit of
randomisation because the intervention targets health-
care professionals who frequently move between teams
within an organisation. Patient- or ward/team-level ran-
domisation is therefore infeasible because of a high cer-
tainty of contamination. A stepped-wedge design is
more efficient for the same number of units than a par-
allel group cluster-randomised trial when the intra-class
correlation coefficient is relatively large and the cluster
sizes are large, because each unit acts as its own control,
reducing variability [40]. Organisations are very large
units of randomisation, but as explained previously, this
is necessary because clinical teams are shared across
organisations so there is no smaller unit of randomisa-
tion that will avoid contamination. Because antibiotic
prescribing activities are based on local organisation
guidelines and culture, we also expect within-
organisation variation to be much smaller than between-
organisation variation. Thus, we anticipate that the
stepped-wedge design will be more efficient for this spe-
cific evaluation study. The stepped-wedge design also
ensures that all participating organisations have the op-
portunity to receive the intervention at some point. This
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is important given the strong interest from organisations
in interventions which could reduce antibiotic consump-
tion, in the face of the emphasis on reducing inappropri-
ate antibiotic use in hospitals from DH and wider
government and financial incentives supporting such re-
ductions [41, 42].
Figure 1 shows how the patient population is defined
from health records. Figure 2 illustrates the analysis
model. Figure 3 shows the ARK schedule of enrolment,
interventions and assessments and Fig. 4 the flow dia-
gram. The Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) checklist is provided
as Additional file 1.
Inclusion/exclusion criteria
Organisations from England and the three devolved na-
tions (Northern Ireland, Wales and Scotland) are eligible
if they are (1) organisations admitting patients to (adult)
acute/general medicine (the target patient population)
(acute or district general trust in England); (2) willing to
implement the intervention in healthcare professionals
involved in antibiotic prescribing or administration in
adult acute/general medicine and able to identify a local
‘champion’ to lead this; and (3) able to provide the re-
quired routine electronic data on adult patients admitted
to acute/general medicine over the required time periods
(see the discussion in subsequent sections). There are no
exclusion criteria. Organisations are identified and
approached through professional networks, the Society
for Acute Medicine, through the clinical research
networks and through word of mouth. Study sites are
listed on http://www.arkstudy.ox.ac.uk/about/.
Intervention
This protocol will test a complex behavioural intervention
for healthcare professionals designed using a ‘person-
based approach’ [43], based on stakeholder workshops
and qualitative studies with healthcare professionals and
patients, to increase the acceptability, feasibility and effect-
iveness of the ‘review and revise’ component of the DH
‘Start Smart then Focus’ strategy. The intervention in-
cludes several components (Santillo M, et al.: Intervention
Planning for the ARK (Antibiotic Review Kit) Interven-
tion: a Digital and Behavioural Intervention to Safely Re-
view and Reduce Antibiotic Prescriptions in Acute and
General Medicine, submitted [44]). They are:
 An evidence-based educational and motivational
website (with mobile-friendly version) including
training in the ARK decision aid (‘online training’)
 The ARK decision aid to classify initial antibiotic
prescriptions based on risk of infection
 Data collection on rates of review and revise, use of
the decision aid and rates of stopping, alongside
regular and supportive discussions with clinical
teams (e.g. through peer-led seminars or ward
rounds) to support staff with implementation and
address any barriers or concerns
 A patient leaflet which healthcare professionals
can provide to acute/general medical inpatients
and their carers to inform and reassure patients
Fig. 1 Defining the patient population from routinely collected electronic health records
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that their antibiotics may be stopped, without
requiring increased consultation time, and to
instruct them to ensure healthcare professionals
are aware if their symptoms worsen. (Mowbray F,
et al.: Patient Engagement with Antibiotic
Messaging in Secondary Care: a Qualitative Study
of the ‘Review & Revise’ Experience,
submitted [45]).
The intervention includes an implementation toolkit to
help the local champion and the implementation team
adopt and adapt the intervention to their local structures.
Relevant local factors include how acute/general medical
services are provided (e.g. acute medical unit, clinical deci-
sion unit, emergency department); when/if staff change post
the initial admission ‘take’ round; who is involved in deci-
sions about continuing or not continuing antibiotics
Fig. 2 Analysis model
Fig. 3 ARK schedule of enrolment, interventions, and assessments (SPIRIT figure). * Healthcare organisations are recruited to the study before enrolment
but at varying calendar times, based on the fact that they can provide historical patient electronic healthcare record data pre-implementation. They are
allocated an implementation date based on the stepped-wedge design. ** Follow-up finishes 12months after the last randomised organisation
implements the intervention, estimated June 2020. † There are no formal assessments. Outcomes are assessed using routinely collected electronic health
records from patients admitted to acute/general medicine over the entire study period, pooled periodically during the trial
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(emergency department, specialists, acute/general physi-
cians); and local prescribing systems (e.g. paper vs elec-
tronic).
To avoid contamination, complete information about
the intervention is released to the local champion at the
point of randomisation, which is 3 months before
anticipated organisation-wide implementation. The
intervention is not blinded; patients who receive the
leaflet or who are aware of study posters will also not be
blinded.
Randomisation
The phase III main trial uses an organisation-
randomised stepped-wedge design in which interven-
tions are successively implemented across different
organisations over time.
The stepped-wedge cluster-randomised main trial uses
calendar-time blocked randomisation. The randomisa-
tion list was drawn up in blocks of 6 before the trial
started. Organisations were added to a separate list of
trial sites based on the date when they joined the ARK
network, divided into groups of 6, with the implementa-
tion date for each organisation then randomly assigned
by the randomisation list (i.e randomisation stratified by
these blocks). This is feasible, because all research data
on which the intervention is evaluated are routine elec-
tronic health record data that are completely independ-
ent of the trial. Thus, they are available historically and
collected in the same way, regardless of the date of ran-
domisation/implementation— there are no research-
specific outcome data in the trial (details in a subsequent
section). Organisations have no control over which block
they are allocated to or to their randomisation date: 24
organisations had already joined the network at the start
of randomisation. This was a pragmatic decision based
on the fact that trusts in the main trial would be rando-
mised over 18 months, and in the current NHS climate
it is impossible to get NHS trusts to agree to join a
programme to reduce antibiotic use where they might
not get the intervention for 18 months. All comparisons
will be made before and after implementation in the
same trust (see the following paragraphs), since any
comparison across trusts pooling time will be irretriev-
ably confounded by various organisational changes in-
ternally and externally.
In practice, the local champions need some lead time
to get an implementation team together, to identify the
essential individuals who drive prescribing decisions for
acute/general medical inpatients at the organisation (in
whom training uptake will be assessed) and to arrange
meetings with staff before implementation. Randomisa-
tion therefore occurs 3 months before the target ‘imple-
mentation date’ (baseline), and the implementation
toolkit contains a focused set of activities from this ran-
domisation date through to implementation.
Randomisation uses computer-generated random
numbers and is based on two to four organisations
implementing per month (on Mondays), avoiding imple-
mentation dates over the summer holidays, Christmas
and Easter. The allocation sequence has been generated
by the Trial Statistician (ASW) and is concealed from
everyone except the Trial Statistician. The Trial Statisti-
cian informs the Trial Manager of the next randomisa-
tion 5 days before the randomisation by email; the Trial
Manager then informs the site by email on the random-
isation day. Any organisation which withdraws from the
trial between randomisation and randomised implemen-
tation date will be replaced, and their electronic research
data will not be collected. They will be reported as a
withdrawal.
Follow-up
The intervention is delivered to healthcare professionals
involved in prescribing or administering antibiotics, but
outcomes are assessed in inpatients admitted to acute/
Fig. 4 SPIRIT 2013 Checklist: Recommended items to address in a
clinical trial protocol and related documents
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general medicine (see the following section). Therefore,
follow-up periods relate to calendar time before and
after implementation intervention. Routinely collected
electronic patient health data are therefore requested
from each organisation from 1 February 2016 (2 years
before the start of phase III), or as close to this as pos-
sible (or up to 2 years pre-implementation for feasibility
and pilot organisations). Final data will be requested on
31 October 2020, 15 months after the last randomised
implementation date, to allow 90-day mortality to be
ascertained on the last patients admitted up to 12
months’ post the last randomised implementation date.
Outcomes and their assessment
The main primary and secondary outcomes will be
assessed using anonymised routine electronic health
records data that are already captured at participating
organisations. These data will be extracted from NHS
databases and anonymised by local organisation in-
formatics/information technology departments (fund-
ing is provided to support this) before sending to the
research team, following a pre-defined data specifica-
tion document detailing data items and coding. All
patients can request that their NHS records not be
released for secondary use (for example, in Hospital
Episode Statistics (HES)). Patients who have opted
out of sending their hospital records to NHS Digital
will not have information submitted for intervention
evaluation.
The phase III main trial has two co-primary outcomes:
 30-day mortality post-admission (non-inferiority)
 DDDs of antibiotics per acute/general medical
admission (superiority).
Admission (rather than bed-day) is the denominator
for this co-primary outcome (similar to the DH Anti-
microbial Prescribing Quality Measures), because bed-
day can be strongly influenced by non-medical reasons
for not discharging inpatients [46, 47]. The reason for
including two co-primary outcomes is to include both a
patient health outcome, where we expect to see no evi-
dence of benefit from using fewer antibiotics, but im-
portantly no evidence of harm; and also an endpoint
reflecting the overarching goal of the intervention,
namely to reduce antibiotic use. However, the full trial
will not evaluate a shorter course of antibiotics per se,
but an intervention designed to reduce antibiotic dur-
ation enacted through healthcare professionals’ behav-
iour. There is therefore no guarantee that it will have
the desired effect on total antibiotic usage: if the inter-
vention does not reduce antibiotic consumption, de
facto it will have failed. For this reason, antibiotic con-
sumption is a co-primary superiority endpoint. The fact
that the primary endpoint (30-day mortality) is for non-
inferiority is another reason for including antibiotic dur-
ation as a co-primary endpoint; the intervention will be
considered successful only if it significantly reduces anti-
biotic usage with no evidence of increased mortality.
No personal data are collected, but as date of death is
considered confidential (but not personal as it does not
relate to a living individual), approval has been obtained
from the Research Ethics Committee (REC) and the
Confidentiality Advisory Group (CAG) for data collec-
tion without individual consent.
The primary and secondary outcomes (Table 1) will be
supplemented by additional quantitative, qualitative and
laboratory data in order to assess uptake, use and other
impacts of the intervention (also listed in Table 1). Gut
flora resistance potential will be assessed using repeated
point prevalence surveys at three organisations, follow-
ing the stepped-wedge randomised design using freshly
discarded faecal samples remaining after Clostridium
difficile testing. Diarrhoea is very common in acute/gen-
eral medical inpatients, with multiple causes, the major-
ity not infectious. All inpatients with diarrhoea will have
samples sent for C. difficile testing, making this a rela-
tively generalisable reflection of the population, particu-
larly of those patients likely to provide the greatest
contribution to spreading resistance elements by the
oral-faecal route (because they have diarrhoea) and who
have received antibiotics (because antibiotics can cause
diarrhoea). Less than 5% test positive for C. difficile; that
is, the actual disease burden is low. Samples will be iden-
tified for the study by staff in the routine service micro-
biology laboratory. They will be analysed for gut flora
‘resistance potential’ without respect to any patient-
identifying information, and ethical approval has been
obtained to do this without individual patient consent.
No single method is currently available to estimate the
‘resistance potential’ of gut microorganisms. Culture is
specific to particular organisms and is practically feasible
for only a small number of species, excluding any that
are non-culturable by default. Targeted molecular ap-
proaches, such as polymerase chain reaction (PCR), can
only identify a subset of thousands of known variants of
antimicrobial resistance (AMR) genes/mutations in a
sample [48]. Because of this, we plan to use metage-
nomic sequencing directly from extracted faecal DNA to
characterise the gut ‘resistance potential’, comparing the
millions of short sequences produced to catalogues of
thousands of AMR genes, and theoretically providing a
quantitative and representative estimate of ‘resistance
potential’ [49, 50].
Process evaluation will also include interviews/focus
groups with healthcare professionals, a brief question-
naire concerning healthcare professionals’ perceived bar-
riers to review and revise (collected online on
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completion of the online training and 1month later) and
healthcare professionals’ usage of the online training
(collected automatically by the website and mobile soft-
ware). Implementation of ARK will also be assessed
using a questionnaire completed by the ARK champion.
There is intense interest in the use of electronic health
records in clinical trials [51]. However, they also have
important challenges, three being notable for the ARK
intervention: defining the intervention population; as-
sessment of antibiotics; and access.
Table 1 Primary, secondary and other objectives and measures in the main trial
Objectives Outcome measures Timepoint(s) of evaluation of this outcome
measure
Co-primary objectives
To compare the effect of introducing the
behavioural intervention on 30-day mortality
post-admission as an acute/general medical in-
patient (non-inferiority)
Death, ascertained from hospital records which
are routinely updated from national death
reporting
30 calendar days after admission to acute/
general medicine
To compare the effect of introducing the
behavioural intervention on antibiotic exposure
per acute/general medical admission (superiority)
Defined daily doses (DDDs) of antibiotics per
acute/general medical admission, ascertained
from electronic hospital prescribing records
Over each acute/general medical admission,
including antibiotics prescribed at discharge
Secondary objectives
To compare the effect of introducing the
behavioural intervention on antibiotic exposure
using different metrics
DDD per occupied bed-day, days on antibiotics
per admission and bed-day (length of therapy
(LOT)),a antibiotic days per admission and bed-
day (days of therapy, DOTa), carbapenem DDD,
DOTa and LOTa (per admission and per bed-day),
broad-spectrum DDD, DOTa and LOTa (per admis-
sion and per bed-day), IV and oral DDD, DOTa
and LOTa (per admission and per bed-day), WHO-
defined ’Access’, ’Watch’ and ’Reserve’ DDD, DOTa
and LOTa (per admission and per bed-day), ’Ac-
cess’ as a percentage of all antibiotic use
Over each acute/general medical admission,
including antibiotics prescribed at discharge
To compare the effect of introducing the
behavioural intervention on adverse outcomes
ICU admission during the current admission, total
length of stay (hours), antibiotic restart after
discontinuation,a emergency re-admission in the
30 days after discharge, C. difficile diarrhoea, mor-
tality over the longer term
ICU admission over the current admission; for
emergency re-admission, up to 30 days post-
discharge; for C. difficile diarrhoea, up to 90
days post-admission; for mortality up to 90
days post-admission
To evaluate the impact of the intervention on
the faecal flora
Proportion of discarded faecal samples from
medical inpatients from which extended
spectrum beta-lactamase (ESBL)-carrying Entero-
bacteriaceae can be isolated
Repeated cross-sectional surveys over time
Tertiary objectives
To evaluate the cost-effectiveness of the behav-
ioural intervention
Resource utilisation and costs Over the current admission and up to 30 days
post-discharge
To quantify uptake and acceptability of the
online training component of the behavioural
intervention (process outcome)
Proportion of locally identified and pre-specified
essential individuals who drive prescribing deci-
sions for acute/general medical inpatients at the
organisation who complete the online training
(recorded electronically by individuals entering
their name and work (NHS) email on the last
page) or on an attendance list if the local organ-
isation has opted to do face-to-face training
sessions
Within 3 months of invitation to complete
training
To quantify uptake of the ARK ‘review and revise’
procedure within the behavioural intervention
(process outcome)
Proportion of regularly audited antibiotics
prescriptions which document the ARK
classification criteria
Proportion of regularly audited antibiotics
prescriptions which are stopped at ‘review and
revise’
Over 12 weeks following implementation date
aIn organisations with individual electronic prescribing (rather than bulk) antibiotic data
Note: WHO definitions of ’Access’, ’Watch’ and ’Reserve’ antibiotics will be used, following the 2017 Essential Medicines List, using the PHE interpretation. Broad-
spectrum is defined as co-amoxiclav; piperacillin/tazobactam; second (e.g. cefuroxime), third (e.g. ceftriaxone ceftazidime) or fourth (e.g. cefepime) generation
cephalosporins or cephalosporin-beta-lactamase inhibitor combinations (e.g. ceftazidime-avibactam, ceftolozane-tazobactam); carbapenems; quinolones;
azithromycin; tigecycline; aztreonam; and telithromycin. Cefaclor is not included as a second generation cephalosporin because it is administered orally and is not
well absorbed
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Firstly, the population receiving the intervention is
(adult) acute/general medical inpatients. However, in prac-
tice different organisations have different patient path-
ways; some organisations retain patients in acute medical
units for the duration of their admission, whereas in
others they swiftly move to related specialties such as
gastroenterology, gerontology, respiratory, etc. Part of the
implementation toolkit involves mapping these patient
flows and involving all relevant clinicians in training.
However, such acute/general medical inpatients are not al-
ways identified by the use of the 300 (general medicine)
specialty code (Fig. 1). In 2017 the Society for Acute
Medicine and the Nuffield Trust (Martin Bardsley, per-
sonal communication) completed an exercise identifying
the most commonly used specialty codes under which
adult acute/general medical inpatients are admitted, and
we follow their definition. The patient population is there-
fore defined by either the treatment specialty code (under
which the patient is treated) (HES “tretspef”) or the main
specialty code (of the consultant) (HES “mainspef”) of ei-
ther the first or second consultant episode for an inpatient
spell, where the inpatient spell has the primary admission
date (HES “admidate”) during the time periods specified
previously. Paediatric admissions have different specialty
codes and are not included in this definition of the ana-
lysis population (and are not exposed to the intervention,
which is implemented in services admitting adult acute/
general medical inpatients).
Because of the potential for exposure misclassification
(which may vary by organisation), sensitivity analyses of
the primary outcomes will be conducted excluding car-
diology (320), rheumatology (410), haematology (303)
and neurology (400). If results provide a qualitatively dif-
ferent interpretation, these sensitivity analyses will be
conducted for all outcomes.
DDDs using standard WHO formulae (www.whocc.
no) are designed to transform milligrams of different
antibiotics into standard units reflecting a typical dose
and are recommended for use in antibiotic evalua-
tions [52]. Their most important limitation is that re-
ducing prescribing of broad-spectrum antibiotics
often involves moving to a combination of multiple
agents of narrower spectrum. A single DDD of a
broad-spectrum antibiotic may therefore be replaced
with multiple DDDs of narrower spectrum antibiotics,
but this is probably better for future antimicrobial re-
sistance. For this reason, where organisations are able
to provide individual-level antibiotic prescribing data,
we will also analyse length of therapy (LOT), defined
as the time (days/hours/minutes) between the last
and first administration of antibiotic treatment (lump-
ing all antibiotics together), and days of therapy
(DOT), defined as the sum of the time (days/hours/
minutes) between the last and first administration of
each separate antibiotic. However, relatively few orga-
nisations currently have individual-level electronic
prescribing systems, and therefore most are only able
to provide bulk-level DDDs in acute/general medical
inpatients.
Admission (rather than bed-day) is the denominator
for antibiotic usage (similar to the UK DH Antimicro-
bial Prescribing Quality Measures), because bed-day
can be strongly influenced by non-medical reasons for
not discharging inpatients. However, this provides a
challenge since it is not straightforward to identify
these admissions from the electronic inpatient admis-
sion records (see the preceding discussion). Where
hospitals provide data on bulk prescriptions only (e.g.
using the JAC or Rx-info systems), they are able to
provide both total DDDs and DDDs per admission to
the relevant hospital areas. The primary analysis will
use this denominator wherever available. Where these
data are not available, we will use estimates of the
relevant admissions and overnight stays from the
population defined above.
The last challenge is obtaining the data from individ-
ual organisations. Most do not have single unified sys-
tems, so patient admissions, antibiotic usage (bulk
DDDs or individual level prescriptions) and C. difficile
data are all held on separate databases and have to be
extracted, merged and pseudo-anonymised by over-
worked information technology departments. This is
proving to be a significant challenge despite £14,000 per
organisation being provided to obtain these data four
times over the course of the trial (for Data Monitoring
Committee [DMC] meetings and final analysis).
Statistical analysis
Analyses will be presented for all organisations. How-
ever, the primary analysis will include only the pilot and
main trial trusts (the pilot trusts are included to maxi-
mise power and because the intervention was essentially
unchanged between the pilot study and the main trial,
and the pilot study sites did not choose their implemen-
tation dates). A sensitivity analysis of the primary out-
comes will include the main trial sites only. If results
provide a qualitatively different interpretation, these sen-
sitivity analyses will be conducted for all outcomes.
The primary analysis method for binary outcomes will
be logistic regression. This is done because, for mortal-
ity, data will be considered to be completely ascertained
on the basis of routine checks that each organisation
conducts against the national death registry, for ex-
ample, to ensure that follow-up letters are not sent to
patients who have died. Therefore, patients not recorded
as dying in the national system will be assumed to be
alive 30 days (co-primary outcome) and 90 days (second-
ary outcome) after admission. The death registry is not
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up to date in real time, and routine checks are only car-
ried out periodically; the final data extract will be re-
quested 6 months after the last included admission to
ensure that ascertainment is as robust as possible. In-
hospital mortality is completely ascertained by discharge
codes. Further, for all binary outcomes, event rates are
relatively low (5–10%), so there is little difference be-
tween analysing a cause-specific hazard or a competing
risks subhazard. Analysing the outcome using logistic
regression also facilitates visualisation of the estimated
pre- and post-implementation trends, and the step
change at implementation, against the observed percent-
ages for each outcome per organisation. Sensitivity ana-
lyses will consider these as time-to-event outcomes and
will consider competing risks from inpatient and out-of-
hospital deaths as relevant for each specific outcome
[53–55]. Negative binomial regression will be used to
model antibiotic DDDs, incorporating over-dispersion
and using different offsets as defined previously. Other
antibiotic outcomes are planned to be analysed using or-
dinal logistic regression; however, if, for example, data
are approximately normally distributed, either before or
after transformation, linear regression may be used in-
stead. Box-Cox-transformed length of stay will be ana-
lysed using normal linear regression. A sensitivity
analysis will include stay only up to the point a patient
was declared medically fit for discharge. A second sensi-
tivity analysis will use quantile regression of the 90th
percentile to assess effects at the extremes of the
distribution.
For analyses comparing periods before and after intro-
duction of the intervention, we hypothesise that the
intervention could produce either a step change in each
outcome, or ongoing changes over time (i.e. an inter-
action between intervention vs control and calendar
time), or both. Analysis will therefore use an interrupted
time series (ITS) analysis which not only estimates
whether the intervention has a direct immediate impact,
but also whether it has any impact on year-on-year
trends after implementation (and compared with year-
on-year trends pre-implementation) (Fig. 2). For ex-
ample, even if there is no immediate impact of the inter-
vention on mortality, it will be particularly important to
monitor, say, whether any calendar year trends suggest
mortality increases post-implementation. It will also be
important to monitor whether antibiotic use declined
faster post- vs pre-implementation.
Other reasons for using the ITS approach within or-
ganisation, and then pooling organisation-level esti-
mates, are that many other things are likely to be
changing differently in different organisations, and
within organisations, over calendar time. For example, fi-
nancial incentives could be introduced to reduce anti-
biotic use in hospital and increase the numbers of
antibiotic prescriptions that receive review (under the
Commissioning for Quality and Innovation [CQUIN])
payments framework). These external factors will affect
within-organisation comparisons less than between-
organisation comparisons. Further rates may not be con-
stant before or after the intervention. Finally the
calendar-time blocked randomisation makes the as-
sumptions underlying the standard vertical comparisons
(between organisations already randomised to interven-
tion vs not at each step) more questionable. The date of
introduction of the intervention will be the planned date
of implementation for the feasibility and internal
pilot organisations and the date that each organisa-
tion was randomised to implement the intervention
in the main trial. Sensitivity analyses for the main
trial will also consider the fact that implementation
may occur gradually over approximately 3 months
[56], by incorporating a trend for the 3 months post-
implementation date instead of a single step change
at the implementation date. The DMC will be asked
to advise on the most appropriate analysis model as
part of their Charter.
Each outcome will first be modelled separately in each
organisation, estimating trends before and after
intervention implementation, plus an implementation-
associated immediate effect (‘step change’) (Fig. 2). The
unit of analysis will be admission. Patient will be used as a
clustering variable for robust variance adjustment (but not
otherwise adjusted for). Based on data available to date,
we do not expect strong seasonal effects in the outcomes
above, but this will be investigated and included if neces-
sary. Meta-analytic techniques will then be used to com-
bine these organisation-specific estimates to produce an
overall intervention effect, assessing heterogeneity using I2
statistics. This approach is similar to a multilevel model,
but it has more flexibility in modelling individual organi-
sations. The primary comparison will be a 2 degree of
freedom test, jointly testing that the ‘step change’ is zero
and that there is no change in calendar trends post- vs
pre-implementation. This joint test will be fitted on model
parameters and explicitly account for correlation between
the two estimands. Secondary analyses will consider calen-
dar trends post-implementation, and change in calendar
trends post- vs pre-implementation, and a trend for imple-
mentation over 3 months rather than a ‘step change’.
The major concern about unadjusted analyses is the
potential for variation in case mix, particularly over a
calendar year, to affect estimates of intervention ef-
fect. Additional sensitivity analyses will adjust for case
mix to assess whether changes in case mix could con-
found any changes in antibiotic use observed over
time. The following admission-level covariates have
been chosen based on their significant effects on 30-
day mortality in previous analyses of emergency
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admissions from routinely collected data [57] and will
be adjusted for in each organisation regardless of stat-
istical significance (with non-linear relationships
between covariates and outcomes assessed and incor-
porated using natural cubic splines): sex; age (years)
at admission; immunosuppression; Charlson Co-
Morbidity Index (defined using secondary diagnosis
codes); interaction between age and Charlson [57];
patient classification; admission method, source, spe-
cialty, day of the week, time of day and day of year
and interaction between admission day of the week
and time of day [57]; number of admissions in previ-
ous year (excluding as day case), and ever had a com-
plex admission.
All analyses will be modified intention-to-treat, includ-
ing all randomised organisations who attempted to imple-
ment the intervention but excluding any organisations
who withdrew between randomisation and randomised
implementation date (who therefore never attempted to
implement the intervention and in whom effects will be
null by definition). It is not possible to specify an
individual-level per-protocol population since the precise
method of management of each individual inpatient is un-
known. All results will be interpreted in the light of the
changes in antibiotic use achieved, both overall and by or-
ganisation. At the organisation level, a per-protocol popu-
lation will be defined broadly by > 50% of locally identified
and pre-specified essential individuals who drive prescrib-
ing decisions for acute/general medical inpatients having
accessed the online training (recorded electronically by
individuals entering their name and work (NHS) email on
the last page or on an attendance list if the local organisa-
tion has opted to do face-to-face training sessions). More
specifically, we specify eight criteria defining implementa-
tion fidelity:
1. Provision of a list of key essential people, by
implementation date
2. Achieving at least 20 people per 100 acute beds
who have done the online learning, by end of
implementation date
3. Introduction of the ARK categories into the
prescribing process, generally by adjusting the
physical drug chart or e-prescribing system. As a
minimum, documentation of categories into clerk-
ing or system to force stop/re-prescribe by 72 h in
e-prescribing, by implementation date
4. Process in place for making patient leaflet
available to acute medical patients, by
implementation date
5. Submission of baseline audit data, by
implementation date
6. Process in place for ongoing audit and feedback, by
implementation date
7. Submission of initial post-implementation audit
data, by week 4
8. Submission of electronic patient research data, by
week 16 following implementation
Failing to meet five or more criteria would be consid-
ered a failure to implement in analysis.
Intervention uptake will be assessed by estimating the
proportion of locally identified and pre-specified essen-
tial individuals who drive prescribing decisions for
acute/general medical inpatients at the organisation who
complete the online training.
Process evaluation analyses will seek to better
understand how ARK was implemented across differ-
ent hospitals, potential barriers and facilitators and
also how implementation influenced use of the inter-
vention and antibiotic use. This will be triangulated
with data from qualitative interviews/focus groups,
which will undergo thematic analysis. Secondary ana-
lyses will consider how much of any effect of the
intervention could be mediated through different as-
pects of the implementation of review and revise, in-
cluding training completion rates, evidence of
implementation from audit records as well as success
of implementation in each hospital, based on mixed
methods evaluation and documentary evidence, and
number of the preceding criteria met.
For the primary endpoint, subgroup analyses will be
conducted by investigating heterogeneity in the
organisation-level intervention effect estimates across
the following factors, using meta-regression techniques:
randomisation block (categorical stratification factor),
calendar period of randomised implementation date
(reflecting different NHS pressures) (Jan–Mar, Apr–Jun,
Jul–Sep, Oct–Dec), organisation type (small, medium,
large, teaching), region, functional role of champion
(acute medicine, microbiology/infectious diseases,
pharmacist), paper vs electronic prescribing systems,
percentage of essential people completing training by 12
weeks, total number completing training by 12 weeks
per 100 acute beds.
Missing data
Other than antibiotics, outcome data and variables for
adjustment are based on routine electronic health re-
cords linked by NHS numbers within participating orga-
nisations. As these records are used for patient
management, data in the variables being requested
should not be missing. As above, for mortality, data will
be considered to be completely ascertained; similarly, for
other outcomes, as follow-up time is relatively short, ob-
served data will be assumed to represent all events
within the prescribed follow-up time (30–90 days).
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For adjustment variables, first if demographics are
missing for only some records for a patient, these will be
carried forwards and backwards to any other records
with missing values. Afterwards, any records with miss-
ing values for any of the key adjustment variables will be
enumerated. If these comprise < 0.1% of records from an
organisation, they will be assumed to represent incorrect
records in the underlying data sources and checked with
the individual organisation, but will be dropped from all
analyses (adjusted and unadjusted). Where records with
missing data comprise > 0.1% of records from an organ-
isation, this will be queried, since it is not anticipated
that this should ever occur with the data items above.
Health economics
A within-trial cost-effectiveness analysis will estimate
and compare the costs and impact of ‘review and revise’
compared to standard care. The primary analysis will
take an NHS perspective based on data collected within
the phase III main trial and supplemented with data
from the literature where necessary (e.g. quality-of-life
estimates). Costs of inpatient stays will be obtained from
the Reference Costs Database (DH). Intervention costs
will be estimated from admission and antibiotic data col-
lected in the main trial. Costs of antibiotics used will be
estimated from the British National Formulary Drugs
and pharmaceutical electronic market information tool
(eMIT) for generic antibiotics, and actual costs (negoti-
ated locally) obtained from participating organisations
(purposively sampled based on size and type). Collecting
such detailed information on actual antibiotic costs is
important, because whilst we expect that the interven-
tion would lead to lower antibiotic use, and hence re-
duced costs, this is not necessarily the case. It might
lead to more confidence in prescribing antibiotics ini-
tially (e.g. following ‘Surviving Sepsis’ [26]) with appro-
priate discontinuation at early review. Costs of tests (e.g.
C-reactive protein) and investigations (e.g. magnetic res-
onance imaging (MRI), ultrasound) will be estimated in
these same organisations.
Providing the main trial demonstrates the intervention
is non-inferior for 30-day mortality and superior for anti-
biotic usage, we will compare the mean per-patient costs,
pre- and post-intervention implementation, and calculate
the difference, and then estimate the incremental cost per
percentage reduction in antibiotic usage (overall and by
organisation). We will then explore alternative thresholds
to examine the maximum willingness to pay for a reduc-
tion in hospital stays, admissions (and emergency re-
admissions), infection recurrences and quality-adjusted
life years gained. A strategy will be deemed cost-effective
if the incremental cost-effectiveness ratio is under this
threshold. Probabilistic sensitivity analysis will address the
joint contribution of parameter uncertainty on decision
uncertainty and provide adequate estimates of expected
cost and effects. This primary analysis will take an NHS
perspective based on resource use within secondary care.
Differences in resource use outside of hospital are impli-
citly assumed to be equal before and after the interven-
tion, and therefore excluded from modelling.
Other analyses
Analysis described above will be conducted on routine
electronic health record data submitted from participat-
ing organisations. However, for English trusts, data on
both antibiotic prescribing and inpatient admissions (not
C. difficile) is available through the English Surveillance
Programme for Antimicrobial Utilisation and Resistance
(ESPAUR), through purchasing data provided to Public
Health England (PHE) from a commercial company and
through HES respectively. This would enable us to con-
duct analyses of mortality, re-admission, length of stay
and DDDs for all trusts in England, according to
whether or not they had implemented ARK within the
trial, to compare pre-implementation trends in all Eng-
lish trusts, and step change and post-implementation
trends in ARK hospitals vs non-ARK hospitals for these
outcomes.
Sample size
For the phase III main trial, based on simulation studies,
the proposed stepped-wedge cluster-randomised design
including data from a minimum of 36 organisations has
> 85% power to exclude a 5% relative increase in 30-day
mortality and to detect a 15% relative reduction in anti-
biotic use associated with the intervention. The 5% rela-
tive non-inferiority margin means that to declare non-
inferiority, the entire 95% confidence interval (CI) for
the relative change in mortality post- vs pre-intervention
has to lie within [0.95,1.05]. For an overall mortality of
9%, this is analogous to being confident that the post-
intervention mortality lies within [8.5%, 9.5%], that is, a
non-inferiority margin of +/− 0.5% on the absolute scale
or 5% on the relative risk or relative odds scale (which
are similar given the low event rates).
This sample size calculation was based on simulation,
given the uncertainties regarding parameters underlying
the study design. Simulations were run 1000 times for
N = 10 to 40 participating organisations in increments of
2 organisations and a relative decrease in antibiotic use
of R = 5% to 20% in increments of 5%. Organisations
were assumed to vary in size with an underlying rate of
acute/general medicine admissions per year from 5000
to 15,000 (uniform distribution), plus one large organisa-
tion of 25,000 admissions per year (estimates based on
acute/general medical admissions in Oxford University
Hospitals (OUH) NHS Foundation Trust, and publicly
available data on the distribution of annual overnight
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stays in all English NHS trusts). Before the intervention
is introduced, each organisation is assumed to have an
underlying rate of 1000 DDDs per acute/general medical
admission drawn from a uniform distribution on 1500–
3000. Each organisation’s 30-day mortality is assumed to
be distributed uniformly between 7 and 10%, independ-
ently of antibiotic prescribing. The intervention was
assumed to decrease DDDs per 1000 admissions by R%
with no effect on mortality: there are no time trends be-
fore or after implementation in either outcome. The
intervention is implemented in two randomly chosen or-
ganisations every month for 18 months, followed by a
further 12 months post-intervention follow-up. Each
month, the number of acute/general medical admissions
is simulated using a Poisson distribution based on the
underlying rate simulated as above. Each month, DDDs
are then simulated from a negative binomial distribution
based on the simulated number of admissions that
month, each organisation’s simulated underlying pre-
scribing rate and whether the month falls before or after
the randomly allocated intervention time. The dispersion
parameter is fixed at 1.15 times the mean, slightly higher
than the estimated dispersion from monthly antibiotic
prescribing in OUH acute/general medical inpatients
[33]. Each month, the 30-day mortality is then simulated
from a binomial distribution based on the simulated
number of admissions that month, with a probability
drawn from a normal distribution centred on each orga-
nisation’s simulated underlying mortality rate with
standard deviation 0.1. Analysis follows the above-
described methods (and Fig. 2). No sample size inflation
was applied to the two co-primary outcomes because
the goal of the non-inferiority comparison is to demon-
strate that the 95% CI around the estimated relative risk
is within a pre-defined non-inferiority margin, rather
than to identify a significant difference.
Ethical issues
As described above, patients who have opted out of
sending their hospital records to NHS Digital would not
have information submitted for intervention evaluation.
A generic poster describing the study is provided to par-
ticipating organisations to be displayed in emergency de-
partments, clinical decision units, acute medical units,
etc., where included patients will be managed. The pos-
ter contains a link to the study’s public webpage, where
more information about the study is provided in lay lan-
guage, and a study-specific email address, through which
patients can contact the research team. The poster also
contains details of the local Principal Investigator or an-
other local NHS professional whom patients can contact
if they have questions or wish to opt out of data
provision. Removing patients’ data would require them
to provide identifiable data on their NHS number and
hospital number. The research team do not hold any
identifiable data; therefore, they would direct such a pa-
tient to their organisation’s local Principal Investigator
to ensure the patient’s data are removed at source at the
participating organisation before anonymised extracts
are sent to the central research team.
Oversight
An independent DMC will review outcome data from the
phase III main trial approximately 6months after it starts
and then approximately every 9months. The DMC is ad-
visory: after each meeting they will make a recommenda-
tion that the trial continue, or be stopped or modified to
the Programme Steering Committee which will meet
every year throughout the programme. The DMC will
consider both clinical and statistical evidence. Statistical
evidence would be based on the Haybittle-Peto rule (p <
0.001 for impact of the intervention): this has the advan-
tage that the number of DMC meetings does not have to
be pre-specified in advance, and the DMC can meet more
frequently as determined by the data. The DMC would
consider both co-primary outcome measures in their de-
liberations regarding trial stopping. Further details of
DMC functioning and the procedures for interim analysis
and monitoring will be specified in a DMC Charter. The
Programme Steering Committee is the executive body.
This independent oversight committee is termed a
Programme Steering Committee rather than a Trial Steer-
ing Committee because the trial is part of a larger
programme, and the Programme Steering Committee pro-
vides consistent independent oversight across the entire
programme of related work.
Main trial status
The first organisation was randomised in the main trial
on 13 November 2017 (under protocol version 4.0) to
implement on 12 February 2018. The last organisation is
planned to be randomised on 1 April 2019 to implement
on 24 June 2019.
The current protocol is version 5.0 (5 November 2018).
All protocols have been approved by the South Central
Oxford C Research Ethics Committee (REC) (17/SC/
0034) and the Confidentiality Advisory Group (CAG) (17/
CAG/0015). Protocol 1.0 (16 December 2016) was sub-
mitted for REC and CAG approval for the three phases of
the study. Version 2.0 (24 March 2017; phase I feasibility
study) incorporated clarifications requested by REC and
CAG including those on opt-out and the electronic health
records analysis population, and increased preparation
time from randomisation to implementation from 3 to 4
months based on experience preparing for the feasibility
study. Version 3.0 (25 September 2017; phase II pilot
study) included further clarifications on the analysis popu-
lation based on advice from the Nuffield Trust and
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extension of process evaluation to include interviews. Ver-
sion 4.0 (6 November 2017; phase III main trial) returned
preparation time from 4 to 3months based on experience
in the internal pilot and removed an acceptability rating
which had not been collected. Version 5.0 (5 November
2018) increased the number of organisations included in
process evaluation and clarified how individuals would be
recruited for these qualitative studies, adding eight criteria
defining implementation fidelity and several other clarifi-
cations regarding objectives, outcome measures, with-
drawal, population and analysis to align with the statistical
analysis plan version 1.0.
Reporting
Final results will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) extension for
stepped-wedge cluster-randomised controlled trials [58].
Data sharing and dissemination
The full protocol is available on http://www.arkstudy.ox.
ac.uk/ark-for-healthcare-professionals/. Over the 4.5 years
of the study, we anticipate including more than 1 million
inpatient admissions from 36 organisations. Given the size
of the final dataset, we have therefore not requested or ob-
tained permission from all the involved organisations for
it to be shared outside the trial team. Dissemination will
include publication in a peer-reviewed journal and presen-
tation at conferences. Authorship will be determined in
accordance with the International Committee of Medical
Journal Editors (ICMJE) guidelines, and other contributors
will be acknowledged. The ARK intervention has been en-
dorsed by key societies including the British Society for
Antimicrobial Chemotherapy (BSAC), the Society for
Acute Medicine, the UK Clinical Pharmacy Association
and the British Infection Association. In collaboration
with Health Education England, BSAC have worked with
the trial team to develop a post-trial version of the inter-
vention which is freely available to all NHS Trusts and
Health Boards (https://portal.elfh.org.uk/Component/De-
tails/582663 and http://bsac-vle.com/ark-the-antibiotic-re-
view-kit/).
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 160 kb)
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